The proteins of lymphocytic choriomeningitis virus (LCMV) contain only three known peptide regions that are processed and then held in place by the MHC class I H-2b (Db) glycoprotein on the cell's surface for recognition by LCMV-specific Db-restricted cytotoxic T lymphocytes (CTL). These peptides are from the glycoprotein (GP), amino acids 33-41 KAVYNFATC (GP1) and 276-286 SGVENPGGYCL (GP2), and the nucleoprotein (NP), 396-404. We have used CTL clones that recognized only GP1, GP2, and NP to select viral variants that upon infecting cells bearing H-2b molecules escaped recognition by virus-specific CTL directed against the viral GP (GP1 + GP2) mutant, termed GPV, or the viral GP and NP (GP1 + GP2 + NP) mutant, termed GPV+NPV. These CTL "escape" variants nevertheless elicited sufficient host-protective activity in vivo to abort acute infection and prevent the occurrence of persistent infection. This protection was CD8+ lymphocyte mediated and associated with the generation of a novel (for H-2b mice) CTL response to the viral L protein. Hence CTL epitopes form a hierarchy, in which responses to "weak" epitopes are suppressed in the presence of "stronger" epitopes. Mutation in the strong epitopes may be of limited biological significance since the host can mount a protective response directed against the second level (weak) epitopes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1006/viro.1995.1426 | DOI Listing |
J Exp Zool A Ecol Integr Physiol
December 2024
Zoology Department, Faculty of Science, Tanta University, Tanta, Egypt.
One neglected zoonotic illness is toxocariasis. There are not enough anthelmintic drugs in the market to treat low-effectiveness toxocariasis against migrating larvae. Therefore, it is critical to find new, safe alternatives to toxocariasis treatment today.
View Article and Find Full Text PDFPLoS Pathog
December 2024
Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota, United States of America.
The Ebola filovirus (EBOV) poses a serious threat to global health and national security. Nanobodies, a type of single-domain antibody, have demonstrated promising therapeutic potential. We identified two anti-EBOV nanobodies, Nanosota-EB1 and Nanosota-EB2, which specifically target the EBOV glycoprotein (GP).
View Article and Find Full Text PDFFront Mol Biosci
December 2024
Biochemistry Division, Chemistry Department, Faculty of Science, Tanta University, Tanta, Egypt.
Background: Doxorubicin (DOX) drugs used in cancer treatment can cause various adverse effects, including hepatotoxicity. Natural-derived constituents have shown promising effects in alleviating chemotherapy-induced toxicities. This study addressed the effect of Avenanthramides-C (AVN-C) treatment in rats with DOX-indued hepatotoxicity.
View Article and Find Full Text PDFHead Neck
November 2024
Department of Otolaryngology - Head and Neck Surgery, Chang Gung Memorial Hospital, Linkou, Taiwan.
Background: This study evaluates the impact of maxillary sinus mucosa preservation on radiographic outcomes after an inferior maxillectomy and soft-tissue free flap reconstruction.
Methods: A total of 90 patients in two cohorts (mucosal sacrifice versus mucosa preservation) were evaluated from an institutional dataset. Imaging was reviewed at set time points and sinus scores were allotted based on a modification of the Lund-MacKay system.
Front Cell Infect Microbiol
October 2024
Department of Biology, University of Rome "Tor Vergata", Rome, Italy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!